GeoVax Prepares to Unveil Q1 2025 Financial Results and Strategic Progress

GeoVax Labs, Inc., a clinical-stage biotechnology company developing innovative vaccines and immunotherapies, is set to report its first quarter 2025 financial results and provide a comprehensive corporate update on May 1, 2025.

The conference call, scheduled for 4:30 p.m. ET, will offer investors and stakeholders detailed insights into the company's progress across its primary research initiatives. GeoVax's current focus encompasses developing advanced vaccines for infectious diseases and therapeutic approaches for solid tumor cancers.

The company's lead clinical program, GEO-CM04S1, represents a next-generation COVID-19 vaccine currently undergoing three Phase 2 clinical trials. These trials are strategically designed to address critical vaccination challenges, including developing primary vaccines for immunocompromised patients and creating more robust booster options for diverse patient populations.

In addition to its infectious disease research, GeoVax is making significant strides in oncology. The company recently completed a multicenter Phase 1/2 clinical trial for Gedeptin®, a novel oncolytic solid tumor gene-directed therapy targeting advanced head and neck cancers. This research underscores the company's commitment to developing innovative cancer treatment approaches.

The upcoming conference call will provide a platform for management to elaborate on the company's financial performance, research progress, and strategic vision. Investors and industry observers can expect comprehensive insights into GeoVax's ongoing clinical trials, technological advancements, and potential future developments.

With a strong intellectual property portfolio supporting its technologies and product candidates, GeoVax continues to position itself as an innovative player in the biotechnology landscape. The May 1 conference call represents an important opportunity for stakeholders to gain deeper understanding of the company's current research initiatives and potential future impact in vaccine development and cancer therapy.